John Engel
Analyst · J.P. Morgan. Please go ahead.
So, there is a lot of questions wrapped up in that question. So, I'll address the front end. Dave, you address the back of it. The front end, look, we've been through a series of cycles previously. I've been in this chair more than a decade now. That's neither good nor bad, expect to say that I did - I weathered the [indiscernible] through the great global recession. And, again, our sales levels were down, as I said, in 25% range across the whole year. And to average out across the whole year, to have that on a full year basis, it was down higher than that as we move - at different parts of the year. And we took a series of actions in waves throughout that year and we're very aggressive with adjusting our cost structure. Our leverage ticked up a little bit, but we also produce very strong free cash flow, because of the counter-cyclical nature of our business model. And then, we pivoted pretty quickly in 2010 into playing offence and then experienced an outstanding run over the next several years of very strong growth. We started playing offense when others hadn't even begun playing defense yet, quite frankly and experienced a several year run, a very strong growth, outstanding pull-through. And so we know how to manage through cycles and we're taking the same actions now. With that said, as I mentioned earlier, it is one big difference and that is we're going to double the size of this company through the transformational acquisition and in combination with Anixter. And that puts us in a very unique position, we think it's a more compelling now, this combination, because the integration plan execution and synergy delivery will be our restructuring that we have - that we reaffirmed here today in terms of the outstanding value creation potential with delivering the various cost synergies, sales growth synergies and cash generation synergies three years out. So, Dave, do you want to maybe tie the question or the answer closed with the leverage view?